P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968764.90228.92 |
| _version_ | 1827331486679826432 |
|---|---|
| author | Stefanie Schalm Yogesh Chutake Susanne Breitkopf Michele Mayo Nancy Dumont Dapeng Chen Vaishali Dixit Rahul Karnik Alice Mcdonald Jessica Filiatrault William Proctor Frank Qi Kan-Nian Hu Matt Weiss Ashwin Gollerkeri Kirti Sharma Joseph D Growney Juliet Williams |
| author_facet | Stefanie Schalm Yogesh Chutake Susanne Breitkopf Michele Mayo Nancy Dumont Dapeng Chen Vaishali Dixit Rahul Karnik Alice Mcdonald Jessica Filiatrault William Proctor Frank Qi Kan-Nian Hu Matt Weiss Ashwin Gollerkeri Kirti Sharma Joseph D Growney Juliet Williams |
| author_sort | Stefanie Schalm |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:36:58Z |
| format | Article |
| id | doaj.art-fca8737a0dd94eb586ac0ead969eb970 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:36:58Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-fca8737a0dd94eb586ac0ead969eb9702024-03-03T09:43:31ZengWileyHemaSphere2572-92412023-08-017e902289210.1097/01.HS9.0000968764.90228.92202308003-00365P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.Stefanie Schalm0Yogesh Chutake1Susanne Breitkopf2Michele Mayo3Nancy Dumont4Dapeng Chen5Vaishali Dixit6Rahul Karnik7Alice Mcdonald8Jessica Filiatrault9William Proctor10Frank Qi11Kan-Nian Hu12Matt Weiss13Ashwin Gollerkeri14Kirti Sharma15Joseph D Growney16Juliet Williams171 Kymera Therapeutics, Oncology, Watertown, United States2 Kymera Therapeutics, Translational Medicines, Watertown, United States3 Kymera Therapeutics, Proteomics, Watertown, United States4 Kymera Therapeutics, Pharmacology, Watertown, United States4 Kymera Therapeutics, Pharmacology, Watertown, United States5 Kymera Therapeutics, DMPK, Watertown, United States5 Kymera Therapeutics, DMPK, Watertown, United States6 Kymera Therapeutics, Computational Biology, Watertown, United States2 Kymera Therapeutics, Translational Medicines, Watertown, United States1 Kymera Therapeutics, Oncology, Watertown, United States7 Kymera Therapeutics, Safety, Watertown, United States9 Kymera Therapeutics, CMC, Watertown, United States9 Kymera Therapeutics, CMC, Watertown, United States10 Kymera Therapeutics, Chemistry, Watertown, United States11 Kymera Therapeutics, Clinical Development, Watertown, United States3 Kymera Therapeutics, Proteomics, Watertown, United States4 Kymera Therapeutics, Pharmacology, Watertown, United States12 Kymera Therapeutics, Head of Research, Watertown, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000968764.90228.92 |
| spellingShingle | Stefanie Schalm Yogesh Chutake Susanne Breitkopf Michele Mayo Nancy Dumont Dapeng Chen Vaishali Dixit Rahul Karnik Alice Mcdonald Jessica Filiatrault William Proctor Frank Qi Kan-Nian Hu Matt Weiss Ashwin Gollerkeri Kirti Sharma Joseph D Growney Juliet Williams P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. HemaSphere |
| title | P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. |
| title_full | P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. |
| title_fullStr | P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. |
| title_full_unstemmed | P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. |
| title_short | P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. |
| title_sort | p464 pulse dosing of potent and selective heterobifunctional mdm2 degrader kt 253 drives tumor regression and demonstrates differentiated pharmacology compared to p53 mdm2 small molecule inhibitors |
| url | http://journals.lww.com/10.1097/01.HS9.0000968764.90228.92 |
| work_keys_str_mv | AT stefanieschalm p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT yogeshchutake p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT susannebreitkopf p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT michelemayo p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT nancydumont p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT dapengchen p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT vaishalidixit p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT rahulkarnik p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT alicemcdonald p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT jessicafiliatrault p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT williamproctor p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT frankqi p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT kannianhu p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT mattweiss p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT ashwingollerkeri p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT kirtisharma p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT josephdgrowney p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors AT julietwilliams p464pulsedosingofpotentandselectiveheterobifunctionalmdm2degraderkt253drivestumorregressionanddemonstratesdifferentiatedpharmacologycomparedtop53mdm2smallmoleculeinhibitors |